Atrial fibrillation+2
Not recruitingStudy on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation
Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation
- Disease:Atrial fibrillationEmbolic stroke+1
- Substances:Acetylsalicylic AcidRivaroxaban
Belgium- Participants:18–64 years · 65+ years
- Substances:Acetylsalicylic Acid
- Sponsor:University Of Ottawa Heart Institute







